Kirk L Pappan1, Adam D Kennedy1, Pilar L Magoulas2, Neil A Hanchard2, Qin Sun2, Sarah H Elsea3. 1. Metabolon, Inc., Morrisville, North Carolina. 2. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. 3. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. Electronic address: elsea@bcm.edu.
Abstract
BACKGROUND: Phenotyping technologies featured in the diagnosis of inborn errors of metabolism, such as organic acid, amino acid, and acylcarnitine analyses, recently have been supplemented by broad-scale untargeted metabolomic phenotyping. We investigated the analyte changes associated with aromatic amino acid decarboxylase (AADC) deficiency and dopamine medication treatment. METHODS: Using an untargeted metabolomics platform, we analyzed ethylenediaminetetraacetic acid plasma specimens, and biomarkers were identified by comparing the biochemical profile of individual patient samples to a pediatric-centric population cohort. RESULTS: Elevated 3-methoxytyrosine (average z score 5.88) accompanied by significant decreases of dopamine 3-O-sulfate (-2.77), vanillylmandelate (-2.87), and 3-methoxytyramine sulfate (-1.44) were associated with AADC deficiency in three samples from two patients. In five non-AADC patients treated with carbidopa-levodopa, levels of 3-methoxytyrosine were elevated (7.65); however, the samples from non-AADC patients treated with DOPA-elevating drugs had normal or elevated levels of metabolites downstream of aromatic l-amino acid decarboxylase, including dopamine 3-O-sulfate (2.92), vanillylmandelate (0.33), and 3-methoxytyramine sulfate (5.07). In one example, a plasma metabolomic phenotype pointed to a probable AADC deficiency and prompted the evaluation of whole exome sequencing data, identifying homozygosity for a known pathogenic variant, whereas whole exome analysis in a second patient revealed compound heterozygosity for two variants of unknown significance. CONCLUSIONS: These data demonstrate the power of combining broad-scale genotyping and phenotyping technologies to diagnose inherited neurometabolic disorders and suggest that metabolic phenotyping of plasma can be used to identify AADC deficiency and to distinguish it from non-AADC patients with elevated 3-methoxytyrosine caused by DOPA-raising medications.
BACKGROUND: Phenotyping technologies featured in the diagnosis of inborn errors of metabolism, such as organic acid, amino acid, and acylcarnitine analyses, recently have been supplemented by broad-scale untargeted metabolomic phenotyping. We investigated the analyte changes associated with aromatic amino acid decarboxylase (AADC) deficiency and dopamine medication treatment. METHODS: Using an untargeted metabolomics platform, we analyzed ethylenediaminetetraacetic acid plasma specimens, and biomarkers were identified by comparing the biochemical profile of individual patient samples to a pediatric-centric population cohort. RESULTS: Elevated 3-methoxytyrosine (average z score 5.88) accompanied by significant decreases of dopamine 3-O-sulfate (-2.77), vanillylmandelate (-2.87), and 3-methoxytyramine sulfate (-1.44) were associated with AADC deficiency in three samples from two patients. In five non-AADCpatients treated with carbidopa-levodopa, levels of 3-methoxytyrosine were elevated (7.65); however, the samples from non-AADCpatients treated with DOPA-elevating drugs had normal or elevated levels of metabolites downstream of aromatic l-amino acid decarboxylase, including dopamine 3-O-sulfate (2.92), vanillylmandelate (0.33), and 3-methoxytyramine sulfate (5.07). In one example, a plasma metabolomic phenotype pointed to a probable AADC deficiency and prompted the evaluation of whole exome sequencing data, identifying homozygosity for a known pathogenic variant, whereas whole exome analysis in a second patient revealed compound heterozygosity for two variants of unknown significance. CONCLUSIONS: These data demonstrate the power of combining broad-scale genotyping and phenotyping technologies to diagnose inherited neurometabolic disorders and suggest that metabolic phenotyping of plasma can be used to identify AADC deficiency and to distinguish it from non-AADCpatients with elevated 3-methoxytyrosine caused by DOPA-raising medications.
Authors: Kelli Goodman; Matthew Mitchell; Anne M Evans; Luke A D Miller; Lisa Ford; Bryan Wittmann; Adam D Kennedy; Douglas Toal Journal: Metabolomics Date: 2021-03-11 Impact factor: 4.290
Authors: Lillian R Thistlethwaite; Xiqi Li; Lindsay C Burrage; Kevin Riehle; Joseph G Hacia; Nancy Braverman; Michael F Wangler; Marcus J Miller; Sarah H Elsea; Aleksandar Milosavljevic Journal: Sci Rep Date: 2022-04-21 Impact factor: 4.996
Authors: Emma Graham; Jessica Lee; Magda Price; Maja Tarailo-Graovac; Allison Matthews; Udo Engelke; Jeffrey Tang; Leo A J Kluijtmans; Ron A Wevers; Wyeth W Wasserman; Clara D M van Karnebeek; Sara Mostafavi Journal: J Inherit Metab Dis Date: 2018-05-02 Impact factor: 4.982
Authors: Karlien L M Coene; Leo A J Kluijtmans; Ed van der Heeft; Udo F H Engelke; Siebolt de Boer; Brechtje Hoegen; Hanneke J T Kwast; Maartje van de Vorst; Marleen C D G Huigen; Irene M L W Keularts; Michiel F Schreuder; Clara D M van Karnebeek; Saskia B Wortmann; Maaike C de Vries; Mirian C H Janssen; Christian Gilissen; Jasper Engel; Ron A Wevers Journal: J Inherit Metab Dis Date: 2018-02-16 Impact factor: 4.982
Authors: Ning Liu; Jing Xiao; Charul Gijavanekar; Kirk L Pappan; Kevin E Glinton; Brian J Shayota; Adam D Kennedy; Qin Sun; V Reid Sutton; Sarah H Elsea Journal: JAMA Netw Open Date: 2021-07-01